2. PI3K/Akt/mTOR Cell Cycle/DNA Damage MAPK/ERK Pathway Stem Cell/Wnt Apoptosis
  3. Akt PI3K PERK p38 MAPK ERK Apoptosis
  4. Anticancer agent 319

Anticancer agent 319 is an anticancer agent. Anticancer agent 319 inhibits the proliferation of liver cancer cells. Anticancer agent 319 inhibits AKT phosphorylation and blocks the PI3K/AKT signaling axis; meanwhile, it inhibits ERK1/2 phosphorylation and blocks the MAPK/ERK signaling axis. Anticancer agent 319 induces G2/M phase cell cycle arrest, triggers apoptosis, and reduces mitochondrial membrane potential in liver cancer cells. Anticancer agent 319 can be used for the research of hepatocellular carcinoma.

For research use only. We do not sell to patients.

Anticancer agent 319

Anticancer agent 319 Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Anticancer agent 319 Related Antibodies

Top Publications Citing Use of Products

View All Akt Isoform Specific Products:

View All Isoforms
Akt Akt1 Akt2 Akt3

View All PI3K Isoform Specific Products:

View All Isoforms
PI3Kα PI3Kβ PI3Kγ PI3Kδ PI3KC2α PI3KC2β PI3KC2γ Vps34 PI3K PI3KC3 p120γ

View All p38 MAPK Isoform Specific Products:

View All Isoforms
p38 MAPK Akt1 p38α p38β MAPK13 p38δ p38γ

View All ERK Isoform Specific Products:

View All Isoforms
ERK ERK1 ERK2 ERK5 ERK8

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Anticancer agent 319 is an anticancer agent. Anticancer agent 319 inhibits the proliferation of liver cancer cells. Anticancer agent 319 inhibits AKT phosphorylation and blocks the PI3K/AKT signaling axis; meanwhile, it inhibits ERK1/2 phosphorylation and blocks the MAPK/ERK signaling axis. Anticancer agent 319 induces G2/M phase cell cycle arrest, triggers apoptosis, and reduces mitochondrial membrane potential in liver cancer cells. Anticancer agent 319 can be used for the research of hepatocellular carcinoma[1].

In Vitro

Anticancer agent 319 (Compound 11e) (48-72 h) potently inhibits the proliferation of human hepatocellular carcinoma cells HepG2 and Hep3B, with IC50 values of 2.22 μM (72 h, HepG2), 4.55 μM (48 h, HepG2) and 4.95 μM (48 h, Hep3B), respectively, but exerts no inhibitory effect on the proliferation of Huh-7 cells[1].
Anticancer agent 319 (2.5-10 μM; 24-48 h) inhibits the migration of human hepatocellular carcinoma cell line HepG2 in a dose-dependent manner[1].
Anticancer agent 319 (2.5-10 μM; 36-48 h) induces G2/M cell cycle arrest, triggers concentration-dependent apoptosis, and reduces mitochondrial membrane potential in human hepatocellular carcinoma HepG2 cells[1].
Anticancer agent 319 (2.5-10 μM; 36 h) dose-dependently inhibits the phosphorylation of AKT (Ser473) and ERK1/2 (Thr202/Tyr204), and blocks the PI3K/AKT and MAPK/ERK signaling axes in human hepatocellular carcinoma HepG2 cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Anticancer agent 319 Related Antibodies

Cell Migration Assay [1]

Cell Line: human hepatocellular carcinoma HepG2 cells
Concentration: 2.5, 5 and 10 μM
Incubation Time: 24 h; 48 h
Result: Inhibited HepG2 cell migration in a dose-dependent manner.
Reduced the wound closure rate to 52.96% (2.5 μM), 27.41% (5 μM), and 13.45% (10 μM) after 48 h, compared to 59.11% in the control group.

Cell Cycle Analysis[1]

Cell Line: human hepatocellular carcinoma HepG2 cells
Concentration: 2.5, 5 and 10 μM
Incubation Time: 36 h
Result: Induced G2/M phase arrest at all concentrations.
Increased the SubG1 (apoptotic) population to approximately 22.33% at 5 μM and 10 μM, indicating DNA fragmentation and apoptosis.

Apoptosis Analysis[1]

Cell Line: human hepatocellular carcinoma HepG2 cells
Concentration: 2.5, 5 and 10 μM
Incubation Time: 48 h
Result: Induced characteristic apoptotic nuclear changes, including condensation and fragmentation, in a dose-dependent manner.
Control cells showed uniform, pale blue nuclear staining.\nIncreased the proportion of both early and late apoptotic cells in a concentration-dependent manner.
Caused significant reductions in viable cells compared to the control.

Western Blot Analysis[1]

Cell Line: human hepatocellular carcinoma HepG2 cells
Concentration: 2.5, 5 and 10 μM
Incubation Time: 36 h
Result: Dose-dependently inhibited the phosphorylation of AKT (Ser473) and ERK1/2 (Thr202/Tyr204).
Nearly completely suppressed phosphorylation at the highest concentration.
Molecular Weight

657.54

Formula

C33H34Cl2N2O8
SMILES

COC([C@@H](NC(CCC(OCCOC1=CC2=C(C3=CC=CC=C3C(O2)=O)C=C1)=O)=O)CC4=CC=C(C=C4)N(CCCl)CCCl)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Anticancer agent 319 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Anticancer agent 319Anticancer agent319Anticancer agent-319AktPI3KPERKp38 MAPKERKApoptosisPKBProtein kinase BPhosphoinositide 3-kinaseProtein kinase R-like endoplasmic reticulum kinasePKR-like endoplasmic reticulum kinaseExtracellular signal regulated kinasesPI3K/AKT signaling axisHep3BERK1/2MAPK/ERK signaling axisHepG2AKTAKT1EGFRMMP9hepatocellular carcinomaInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Anticancer agent 319
Cat. No.:
HY-183316
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.